These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38357286)

  • 1. Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity.
    Flury P; Breidenbach J; Krüger N; Voget R; Schäkel L; Si Y; Krasniqi V; Calistri S; Olfert M; Sylvester K; Rocha C; Ditzinger R; Rasch A; Pöhlmann S; Kronenberger T; Poso A; Rox K; Laufer SA; Müller CE; Gütschow M; Pillaiyar T
    ACS Pharmacol Transl Sci; 2024 Feb; 7(2):493-514. PubMed ID: 38357286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization.
    Ciaglia T; Vestuto V; Di Sarno V; Musella S; Smaldone G; Di Matteo F; Napolitano V; Miranda MR; Pepe G; Basilicata MG; Novi S; Capolupo I; Bifulco G; Campiglia P; Gomez-Monterrey I; Snoeck R; Andrei G; Manfra M; Ostacolo C; Lauro G; Bertamino A
    Eur J Med Chem; 2024 Feb; 266():116128. PubMed ID: 38232463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L.
    Ma XR; Alugubelli YR; Ma Y; Vatansever EC; Scott DA; Qiao Y; Yu G; Xu S; Liu WR
    ChemMedChem; 2022 Jan; 17(1):e202100456. PubMed ID: 34242492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-Masked Aldehyde Inhibitors of Human Cathepsin L Are Potent Anti-CoV-2 Agents.
    Zhu J; Li L; Drelich A; Chenna BC; Mellott DM; Taylor ZW; Tat V; Garcia CZ; Katzfuss A; Tseng CK; Meek TD
    Front Chem; 2022; 10():867928. PubMed ID: 35860632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CL
    Yang H; You M; Shu X; Zhen J; Zhu M; Fu T; Zhang Y; Jiang X; Zhang L; Xu Y; Zhang Y; Su H; Zhang Q; Shen J
    Eur J Med Chem; 2023 Sep; 257():115512. PubMed ID: 37253309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19.
    Steuten K; Kim H; Widen JC; Babin BM; Onguka O; Lovell S; Bolgi O; Cerikan B; Neufeldt CJ; Cortese M; Muir RK; Bennett JM; Geiss-Friedlander R; Peters C; Bartenschlager R; Bogyo M
    ACS Infect Dis; 2021 Jun; 7(6):1457-1468. PubMed ID: 33570381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Inhibitors of Main Protease (M
    Mondal S; Chen Y; Lockbaum GJ; Sen S; Chaudhuri S; Reyes AC; Lee JM; Kaur AN; Sultana N; Cameron MD; Shaffer SA; Schiffer CA; Fitzgerald KA; Thompson PR
    J Am Chem Soc; 2022 Nov; 144(46):21035-21045. PubMed ID: 36356199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
    Breidenbach J; Lemke C; Pillaiyar T; Schäkel L; Al Hamwi G; Diett M; Gedschold R; Geiger N; Lopez V; Mirza S; Namasivayam V; Schiedel AC; Sylvester K; Thimm D; Vielmuth C; Phuong Vu L; Zyulina M; Bodem J; Gütschow M; Müller CE
    Angew Chem Int Ed Engl; 2021 Apr; 60(18):10423-10429. PubMed ID: 33655614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114596. PubMed ID: 35839690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety.
    Zhu M; Fu T; You M; Cao J; Yang H; Chen X; Zhang Q; Xu Y; Jiang X; Zhang L; Su H; Zhang Y; Shen J
    Bioorg Med Chem; 2023 May; 87():117316. PubMed ID: 37187077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
    Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J
    Eur J Med Chem; 2023 Nov; 259():115667. PubMed ID: 37482021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
    Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.
    Bai B; Arutyunova E; Khan MB; Lu J; Joyce MA; Saffran HA; Shields JA; Kandadai AS; Belovodskiy A; Hena M; Vuong W; Lamer T; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
    RSC Med Chem; 2021 Oct; 12(10):1722-1730. PubMed ID: 34778773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease.
    Huang C; Zeng R; Qiao J; Quan B; Luo R; Huang Q; Guo N; Li Y; Long X; Ma R; Xia A; Fang Z; Wang Y; Li Y; Zheng Y; Li L; Lei J; Yang S
    Eur J Med Chem; 2023 Nov; 259():115657. PubMed ID: 37517202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.
    Mellott DM; Tseng CT; Drelich A; Fajtová P; Chenna BC; Kostomiris DH; Hsu J; Zhu J; Taylor ZW; Kocurek KI; Tat V; Katzfuss A; Li L; Giardini MA; Skinner D; Hirata K; Yoon MC; Beck S; Carlin AF; Clark AE; Beretta L; Maneval D; Hook V; Frueh F; Hurst BL; Wang H; Raushel FM; O'Donoghue AJ; de Siqueira-Neto JL; Meek TD; McKerrow JH
    ACS Chem Biol; 2021 Apr; 16(4):642-650. PubMed ID: 33787221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity.
    Desantis J; Bazzacco A; Eleuteri M; Tuci S; Bianconi E; Macchiarulo A; Mercorelli B; Loregian A; Goracci L
    Eur J Med Chem; 2024 Mar; 268():116202. PubMed ID: 38394929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subnanomolar Cathepsin S Inhibitors with High Selectivity: Optimizing Covalent Reversible α-Fluorovinylsulfones and α-Sulfonates as Potential Immunomodulators in Cancer.
    Fuchs N; Meta M; Lantzberg B; Bros M; Ling Kuan S; Weil T; Schirmeister T
    ChemMedChem; 2023 Aug; 18(15):e202300160. PubMed ID: 37222230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olgotrelvir, a dual inhibitor of SARS-CoV-2 M
    Mao L; Shaabani N; Zhang X; Jin C; Xu W; Argent C; Kushnareva Y; Powers C; Stegman K; Liu J; Xie H; Xu C; Bao Y; Xu L; Zhang Y; Yang H; Qian S; Hu Y; Shao J; Zhang C; Li T; Li Y; Liu N; Lin Z; Wang S; Wang C; Shen W; Lin Y; Shu D; Zhu Z; Kotoi O; Kerwin L; Han Q; Chumakova L; Teijaro J; Royal M; Brunswick M; Allen R; Ji H; Lu H; Xu X
    Med; 2024 Jan; 5(1):42-61.e23. PubMed ID: 38181791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
    Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
    Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.